How should kidney function be monitored during Cetuximab therapy?

Serum magnesium at baseline and weekly during treatment (the label's cadence); Continue monitoring magnesium for ~8 weeks after the last dose (cumulative deficit, slow recovery); Co-monitor calcium and potassium (secondary hypocalcemia/hypokalemia, refractory until Mg corrected); ECG/QT interval if magnesium is severely low or the patient is symptomatic; Consider 24-h urinary magnesium or fractional excretion of Mg if renal vs GI source is unclear.

How can kidney injury from Cetuximab be prevented?

Replete proactively rather than waiting for symptoms; consider oral Mg maintenance in patients trending down Review and minimize concurrent magnesium-wasting drugs (diuretics, PPIs, aminoglycosides, cisplatin) where feasible

Who is at higher risk of kidney injury from Cetuximab?

Longer cumulative treatment duration (deficit deepens over months); Older age; Concurrent cisplatin or other tubulotoxic chemotherapy; Loop or thiazide diuretics; Baseline low-normal magnesium or poor nutritional/GI magnesium intake; Combination with FOLFIRI/FOLFOX (added GI losses from diarrhea).

Back to explorer

Printable monograph

Anti-EGFR antibody

Cetuximab

Erbitux · Cetux

Anti-EGFR antibody · approved 2004 · 13 citations · FAERS AKI reporting ROR 1.20 (95% CI 1.06–1.35, 270 AKI reports)

Aging evidence· through 2022

Deeply sourced8/9 · 7 signals

Met: 13 citations
Met: 12+ references
Met: Accrued over 10+ years (span: 15y)
Met: Beyond single case reports
Met: High-impact journal
Met: Landmark reference
Not met: Current through 2022
Met: Real-world FAERS signal

Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.

EGFR blockade at the distal convoluted tubule silences the TRPM6 magnesium channel, causing renal magnesium wasting rather than structural kidney injury.

MildAnti-EGFR monoclonal antibody

RAS wild-type metastatic colorectal cancerSquamous cell carcinoma of head & neck

§01

Signature kidney injury

Signature lesion

Electrolyte Disturbance

Representative incidence36%

22–54% 95% CI

Hypomagnesemia is an on-target class effect. In the defining prospective cohort (Tejpar, Lancet Oncol 2007), 95/98 patients (97%) developed a declining serum magnesium slope on EGFR-antibody therapy. Cetuximab-specific pooled data give an any-grade incidence of ~36% (Cao, Chemotherapy 2010; 19 trials, 95% CI 22-54%), with grade 3-4 hypomagnesemia — a CTCAE serum-magnesium threshold, not a symptom rate — in roughly 5-6%; a pooled analysis of randomized anti-EGFR antibody trials (cetuximab and panitumumab together) reports an overall any-grade incidence of 17% across the class (Petrelli, Expert Opin Drug Saf 2011). Versus control, the relative risk is ~3.9 for cetuximab specifically and ~5.83 across anti-EGFR antibodies (Petrelli, Expert Opin Drug Saf 2011). Magnesium falls cumulatively, deepening with treatment duration.Source: Cao, Chemotherapy 2010 (meta-analysis)

Onset & rechallenge

Time to injurySubacute (~1–6 weeks)

Develops over weeks to months of therapy; cumulative, deepest deficits appear late.

Distilled from: “Develops insidiously over weeks to months of therapy and is cumulative — the nadir deepens the longer treatment continues, so the largest deficits typically appear after several months.”

Long-term outlook & thresholds

Renal recoveryUsually reversible

The lesion is a reversible defect in renal magnesium reabsorption, not structural injury: the prospective cohort found serum magnesium falling in 95 of 98 patients (97%) on EGFR-targeting antibodies, with 24-h urine and IV magnesium-load testing localizing the defect to the kidney. Repletion rather than drug discontinuation is the default response while therapy continues. That study's primary outcome was the on-treatment magnesium slope; it does not quantify a post-cessation recovery window, so none is stated here. GFR and serum creatinine are preserved, so it does not drive CKD progression.PMID 17466895 (opens PubMed in a new tab)

Early-detection biomarkers

Serum magnesium — Distal-tubule (DCT) TRPM6 magnesium-channel activity blocked by EGFR inhibition. The signature lab abnormality — magnesium falls cumulatively (a declining slope developed in 95 of 98 [97%] of a prospective cohort on EGFR-targeting antibodies, of which cetuximab was one agent rather than the whole cohort) and must be checked specifically because creatinine and GFR stay normal. The study sets no monitoring interval; the schedule this profile lists comes from the label, which asks for weekly checks for hypomagnesemia, hypocalcemia and hypokalemia during treatment and for at least 8 weeks after the last dose.PMID 17466895 (opens PubMed in a new tab)
Fractional excretion of magnesium (FEMg) / 24-h urinary magnesium — Renal magnesium handling — distinguishes renal wasting from GI/dietary loss. An inappropriately high FEMg (>2-4%) or ongoing urinary magnesium despite hypomagnesemia localizes the defect to the kidney; 24-h urine and IV magnesium-load testing pinned the loss to impaired renal magnesium reabsorption, versus low FEMg (<2%) when the kidney conserves appropriately (GI source).PMID 17466895 (opens PubMed in a new tab)

Long-term outcome and threshold data distilled from the agent's cited literature — educational, not a substitute for the primary sources.

Recovery across agents

§02

Renal toxicities, ranked

This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.

Electrolyte Disturbance#1 · Signaturequalitative — no citable incidence
Renal electrolyte derangement — magnesium/potassium/calcium wasting (cisplatin, anti-EGFR antibodies) or retention (FGFR-inhibitor hyperphosphatemia, tumor-lysis hyperkalemia/hyperphosphatemia).
Glomerular Injury / ProteinuriaRarequalitative — no citable incidence
Biopsy-documented GN and nephrotic syndrome across independent case reports, improving on discontinuation.

Toxicity fingerprint

Tap a signature to trace where it strikes the nephron.

36%incidence

SeverityMild

ReversibilityReversible

Evidence13 citations

Nephron map

Glomerulus

Distal Tubule / Collecting DuctFine-tuning of Na, K, Mg, acid & water

Electrolyte Disturbance

Renal electrolyte derangement — magnesium/potassium/calcium wasting (cisplatin, anti-EGFR antibodies) or retention (FGFR-inhibitor hyperphosphatemia, tumor-lysis hyperkalemia/hyperphosphatemia).

§03

Kidney injury

Deep diveEGFR-inhibitor hypomagnesemiaBy occupying the EGF receptor that keeps the TRPM6 channel trafficked to the apical membrane of the distal tubule, cetuximab and panitumumab convert the kidney into a magnesium sieve — an on-target, designed-in toxicity that deepens the longer the drug keeps working.

Mechanism of kidney injury

EGF, cleaved from pro-EGF at the basolateral membrane of distal convoluted tubule (DCT) cells, is a magnesiotropic hormone: it binds basolateral EGFR to sustain the apical channel TRPM6, the principal route of Mg2+ entry (Groenestege, JCI 2007; Ellison, NDT 2008). Cetuximab blocks EGFR and removes this stimulus, so TRPM6 activity falls and the DCT can no longer reclaim filtered magnesium — producing renal magnesium wasting with an inappropriately high fractional excretion of Mg despite hypomagnesemia. GFR and serum creatinine are preserved: this is a tubular electrolyte-handling defect, not structural AKI. In-vitro work also implicates reduced intestinal (gut TRPM6) Mg absorption (Pietropaolo, Nutrients 2020). Magnesium depletion secondarily impairs PTH secretion/action and distal potassium retention, producing hypocalcemia and hypokalemia that stay refractory until magnesium is restored.

Clinical presentation

Most often an asymptomatic laboratory finding on routine chemistry. Symptomatic hypomagnesemia causes fatigue, muscle cramps, tremor, paresthesias, tetany and, when severe, seizures or cardiac arrhythmia (QT prolongation, torsades). Because magnesium is required for PTH action and distal K+ handling, patients frequently show accompanying hypocalcemia and hypokalemia that resist calcium/potassium repletion alone. Serum creatinine and GFR remain normal.

Management

Repletion, not dose reduction, is the mainstay — the antibody is not renally cleared and cetuximab dosing is not altered for the electrolyte defect. Oral magnesium (e.g., magnesium oxide or glycinate) is first-line for mild deficits but is limited by diarrhea and by the same TRPM6 blockade in the gut. Moderate-to-severe or symptomatic hypomagnesemia needs intravenous magnesium sulfate, often recurrently (e.g., several grams IV every 1-2 weeks), because ongoing renal wasting makes repletion transient while therapy continues. Correct magnesium first: coexisting hypocalcemia and hypokalemia are frequently refractory until magnesium is restored. A potassium-sparing diuretic (amiloride) is sometimes used to blunt distal Mg loss in refractory cases. Grade 3-4 or symptomatic (arrhythmia, tetany) hypomagnesemia may warrant holding cetuximab until corrected. Magnesium supplementation does not appear to impair cetuximab's antitumor efficacy (Pietropaolo, Nutrients 2020).Lesion-level management framework

Risk factors

Longer cumulative treatment duration (deficit deepens over months)
Older age
Concurrent cisplatin or other tubulotoxic chemotherapy
Loop or thiazide diuretics
Baseline low-normal magnesium or poor nutritional/GI magnesium intake
Combination with FOLFIRI/FOLFOX (added GI losses from diarrhea)

Prevention

Replete proactively rather than waiting for symptoms; consider oral Mg maintenance in patients trending down
Review and minimize concurrent magnesium-wasting drugs (diuretics, PPIs, aminoglycosides, cisplatin) where feasible

Anticancer mechanism· how it treats cancer

Chimeric (mouse/human) IgG1 monoclonal antibody that competitively binds the epidermal growth factor receptor (EGFR/HER1), blocking ligand binding and downstream RAS-RAF-MAPK and PI3K-AKT proliferative signaling; the IgG1 backbone also recruits antibody-dependent cell-mediated cytotoxicity (ADCC). Approved for RAS wild-type metastatic colorectal cancer and squamous cell carcinoma of the head and neck (activity in mCRC is confined to KRAS/RAS wild-type tumors).

Note · Incidence estimates derive largely from metastatic colorectal and head-and-neck cancer trial populations and vary with monitoring intensity and concurrent chemotherapy. This is a functional distal-tubule electrolyte-handling defect (renal magnesium wasting), not structural acute kidney injury — GFR and creatinine are preserved. Panitumumab (fully human anti-EGFR IgG2) produces the same, and by some analyses greater, magnesium wasting. Educational content, not medical advice.

§04

Clinical depth

Renal dose adjustment

No renal dose adjustment. Cetuximab is a ~152 kDa IgG1 antibody cleared by reticuloendothelial catabolism, not glomerular filtration, so kidney function does not change its exposure and no reduction is needed in CKD. The management problem is electrolyte monitoring and repletion, not dosing.

Dialyzability & ESKD dosing

Not dialyzable — an IgG1 monoclonal antibody is far too large to cross dialysis membranes and stays confined to the vascular compartment. Hemodialysis neither removes cetuximab nor corrects the underlying tubular defect; note that dialysis can itself remove magnesium, so Mg status still needs attention in dialysis patients.

Differential diagnosis

The hallmark is renal magnesium wasting — an inappropriately high fractional excretion of magnesium (FEMg >2-4%, or ongoing urinary Mg despite hypomagnesemia) with preserved GFR. Contrast with: GI/dietary losses (diarrhea, malabsorption) where the kidney conserves appropriately and FEMg is low (<2%); PPI-associated hypomagnesemia (also gut TRPM6-mediated — check the med list); cisplatin tubulopathy (renal Mg wasting too, but usually accompanied by a rising creatinine/AKI and multi-electrolyte loss); Gitelman syndrome or thiazide/loop diuretics (renal Mg + K wasting in a chronic/drug context); and refractory hypocalcemia/hypokalemia that is actually magnesium-dependent and corrects only once Mg is replaced.

Monitoring

Serum magnesium at baseline and weekly during treatment (the label's cadence)
Continue monitoring magnesium for ~8 weeks after the last dose (cumulative deficit, slow recovery)
Co-monitor calcium and potassium (secondary hypocalcemia/hypokalemia, refractory until Mg corrected)
ECG/QT interval if magnesium is severely low or the patient is symptomatic
Consider 24-h urinary magnesium or fractional excretion of Mg if renal vs GI source is unclear

Key trials & series

CRYSTAL (Van Cutsem, NEJM 2009) — cetuximab + FOLFIRI first-line in EGFR-positive mCRC improved PFS, with benefit confined to KRAS/RAS wild-type tumors; the pivotal front-line context in which cumulative hypomagnesemia is observed.
Tejpar (Lancet Oncol 2007) — prospective cohort (n=98): 97% develop a declining magnesium slope, with urine and IV Mg-load testing localizing a renal magnesium-reabsorption defect; the defining cetuximab-specific renal Mg-wasting study.
Petrelli meta-analysis (Expert Opin Drug Saf 2011) — pooled randomized trials of both anti-EGFR antibodies (cetuximab and panitumumab): any-grade hypomagnesemia 17% in the combined treated population, overall RR 5.83 (cetuximab RR 3.87, panitumumab RR 12.55) vs controls.
Cao meta-analysis (Chemotherapy 2010) — 19 trials/4,559 patients: all-grade hypomagnesemia ~36%, grade 3-4 ~5.6%.

Clinical pearls

Cetuximab hypomagnesemia is a distal-tubule TRPM6 signaling problem, not kidney damage — creatinine and GFR stay normal, so a normal renal panel does not exclude it; you must check magnesium specifically.
It is cumulative: magnesium drifts down over months and the deepest deficits appear late, so a normal early level is not reassurance — keep monitoring throughout therapy and for weeks after stopping.
Oral magnesium is limited by diarrhea and by the same TRPM6 blockade in the gut, so moderate-severe deficits usually need recurrent IV magnesium because renal wasting continues as long as cetuximab does.
Repleting magnesium does not appear to compromise cetuximab's antitumor effect (Pietropaolo 2020), and the picture reverses within weeks of stopping the drug — so aggressive supplementation, not drug discontinuation, is the default response.
Biopsy-documented glomerulonephritis (IgA-dominant proliferative, crescentic) and nephrotic syndrome are attributed to cetuximab across independent reports, improving on discontinuation — mirrored by panitumumab, suggesting an anti-EGFR antibody mechanism.

Beyond the kidney — non-renal toxicities· 3 organ systems

Class-level context for the major non-renal toxicities of the Anti-EGFR antibody class.

Dermatologic

Rash, HFS, SJS/TEN, vitiligo

Acneiform rash, paronychia

Gastrointestinal

Diarrhea, colitis, mucositis, perforation

Diarrhea

Pulmonary

Pneumonitis, ILD, effusions, hypertension

Interstitial lung disease (EGFR TKIs)

§05

References

10 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.

Evidence accrual

10 references · 2007–2022 · 2 since 2020

Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.

Case reports — ranked by strength· 3

Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.

CaseB · ModerateRefractory hypokalemia caused by cetuximab with advanced colorectal cancer patients: the case series and literature review.Chen YW et al. · Anticancer Drugs 2022 · PMID 34419963Case series of refractory hypokalemia (renal potassium wasting) directly attributable to cetuximab, occurring without accompanying hypomagnesemia.CaseC · LimitedDurable complete remission following anti-EGFR antibodies in recurrent metastatic colorectal cancer.Boudrias-Dalle E et al. · J Oncol Pharm Pract 2019 · PMID 28950807Case of persistent grade III hypomagnesemia (renal magnesium wasting) from cetuximab then panitumumab refractory to amiloride and oral/IV magnesium repletion.CaseC · Limited"Ghosts in my body": Seizure-like presentation of hypocalcemic tetany secondary to hypomagnesemia in a patient receiving cetuximab therapy for metastatic medulloblastoma.Kidwell KS et al. · J Pediatr Hematol Oncol 2014 · PMID 23426003Pediatric case of cetuximab causing severe renal magnesium/calcium/potassium wasting (via blockade of renal EGFR-mediated reabsorption) presenting as hypocalcemic tetany.

FDA label — boxed warning & renal dosing· boxed warning

Quoted verbatim from this agent's current FDA label (Apr 2026) — not paraphrased or interpreted. Full label on DailyMed .

Boxed warning

WARNING: INFUSION REACTIONS and CARDIOPULMONARY ARREST Infusion Reactions: ERBITUX can cause serious and fatal infusion reactions [see Warnings and Precautions ( 5.1 ), Adverse Reactions ( 6 )] . Immediately interrupt and permanently discontinue ERBITUX for serious infusion reactions [see Dosage and Administration ( 2.5 )] . Cardiopulmonary Arrest: Cardiopulmonary arrest or sudden death occurred in patients with squamous cell carcinoma of the head and neck receiving ERBITUX with radiation therapy or a cetuximab product with platinum-based therapy and fluorouracil. Monitor serum electrolytes, including serum magnesium, potassium, and calcium, during and after ERBITUX administration [see Warnings and Precautions ( 5.2 , 5.6 )] . WARNING: INFUSION REACTIONS and CARDIOPULMONARY ARREST See full prescribing information for complete boxed warning. ERBITUX can cause serious and fatal infusion reactions. ( 5.1 , 6 ) Immediately interrupt and permanently discontinue ERBITUX for serious infusion reactions. ( 2.5 ) Cardiopulmonary arrest or sudden death occurred in patients with squamous cell carcinoma of the head and neck receiving ERBITUX with radiation therapy or with a cetuximab product with platinum-based therapy and fluorouracil. Monitor serum electrolytes, including serum magnesium, potassium, and calcium, during and after ERBITUX administration. ( 5.2 , 5.6 )

What gets reported — FAERS

Everything below is FAERS — adverse events someone chose to report, about 31,150 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.

Reporting odds ratio (ROR) — is kidney injury named in this agent's reports more often than in every other drug's? Above 1 means yes, disproportionately.
Renal phenotypes — the same question asked separately for each kind of kidney injury, so the ratios differ from the overall one and from each other.
Outcomes — a share of this agent's own reports, not of patients: how many were filed as involving a death or a hospitalization. Not a case-fatality rate.

FAERS reported renal phenotypes· 5 signals

Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-10-01.

What reporting says about this profile's documented lesions

Electrolyte Disturbancecorroborated · ROR 5.08 — on the terms that name the lesion (ROR 30.76)
Glomerular Injury / Proteinuriacorroborated · ROR 2.07 — on the terms that name the lesion (ROR 1.65)

Electrolyte Disturbance

ROR 5.0895% CI 4.81–5.36· 1,382 reports

SIADH / Hyponatremia

ROR 3.0195% CI 2.71–3.34· 356 reports

Glomerular Injury / Proteinuria

ROR 2.0795% CI 1.68–2.54· 89 reports

Thrombotic Microangiopathy

ROR 1.8395% CI 1.35–2.48· 42 reports

Acute Tubular Necrosis

ROR 1.7895% CI 1.21–2.62· 26 reports

FAERS outcomes & reporting trend· 13.5% of reports w/ death · 40.2% w/ hospitalization

13.5%

Reported with a death outcome

4,216 of 31,150 reports

40.2%

Reported with hospitalization

12,521 of 31,150 reports

Reports per year

Yearly FAERS report volume · most recent year is partial.

FAERS adverse-event signal — all organ systems· 8 systems · 31,150 reports

Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-10-01.

Disproportionality (acute kidney injury):ROR 1.2095% CI 1.06–1.35· 270 AKI reports ·AKI is reported disproportionately more often than for other drugs (CI entirely above 1) — a hypothesis-generating signal, not proof of causation.

Gastrointestinal

Diarrhoea2,023Nausea1,645Vomiting1,395Mucosal Inflammation826Stomatitis672

Blood & lymphatic

Neutropenia1,225Anaemia926White Blood Cell Count Decreased756Thrombocytopenia722Myelosuppression619

Skin

Rash2,273Dermatitis Acneiform851Pruritus689

General / constitutional

Pyrexia1,124Fatigue1,076Asthenia848Weight Decreased685

Immune / infection

Infusion Related Reaction1,104Pneumonia645Hypersensitivity639

Metabolic & electrolyte

Dehydration1,102Decreased Appetite867

Respiratory

Dyspnoea1,386

Vascular

Hypotension922

Guidelines & consensus· 13

Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.

General onco-nephrology references

ADQIThe nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroupNat Rev Nephrol 2026 · PMID 41361704Provides expert-based statements (modified Delphi) on preventing and managing cisplatin/platinum-associated AKI, including isotonic IV hydration, attention to volume status and concomitant nephrotoxins, and incorporates evidence that IV magnesium supplementation may reduce cisplatin-associated AKI; emphasizes risk stratification and standardized AKI definitions.SIRMSIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM)Radiol Med 2022 · PMID 35303246Recommends eGFR-based renal risk assessment and pre/post-contrast isotonic saline or sodium bicarbonate hydration; advises maintaining a 5-7 day interval between iodinated contrast administration and cisplatin in cancer patients to reduce additive nephrotoxicity.KDIGOKDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancerKidney Int 2020 · PMID 33126977Identifies platinum compounds (especially cisplatin) as leading cytotoxic causes of acute tubular injury, AKI, and electrolyte/magnesium wasting; calls for interdisciplinary onco-nephrology care, accurate GFR estimation, and individualized drug dosing in patients with reduced kidney function.KDIGOKDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantationKidney Int 2020 · PMID 33276867Addresses chemotherapy-associated AKI/CKD in hematologic cancer, GFR estimation and chemotherapy dosing in patients with reduced kidney function, and management priorities and research gaps for onco-nephrology care.ADDIKDIntegrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practiceEClinicalMedicine 2025 · PMID 40290844Provides GRADE-based, drug-specific dose-adjustment recommendations for anticancer agents in kidney dysfunction (illustrated for methotrexate, cisplatin, carboplatin and nivolumab); the recommendations build on Part 1's standardised CKD-EPI eGFR assessment rather than Cockcroft-Gault creatinine clearance.ADDIKDAligning kidney function assessment in patients with cancer to global practices in internal medicineEClinicalMedicine 2025 · PMID 40290845Three consensus recommendations: assess kidney function by GFR (measured GFR or CKD-EPI eGFR), classify it using KDIGO categories, and use this uniform approach to dose anticancer drugs — moving cancer medicine away from Cockcroft-Gault estimated creatinine clearance.ADDIKDA methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney functionEClinicalMedicine 2025 · PMID 40290846Establishes that, where RCT evidence is lacking, anticancer drug dosing recommendations in kidney dysfunction should be derived by critically appraising observational literature via GRADE combined with structured international multidisciplinary consensus voting.KDIGODiagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)Crit Care 2013 · PMID 23394211Defines/stages AKI by serum creatinine and urine output; emphasizes avoiding nephrotoxins, maintaining euvolemia/perfusion, dose-adjusting drugs to kidney function, and monitoring high-risk patients — the framework applied to nephrotoxic anti-cancer agents.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknownsKidney Int 2024 · PMID 38519239Evaluate and risk-stratify CKD, manage to delay progression and its complications, and practise explicit medication management and drug stewardship — the framework the atlas's G1–G5 eGFR banding and every renal dose-adjustment recommendation sit inside. Because the guideline excludes dialysis and transplant recipients by its own statement of scope, its recommendations do not carry to those settings, where this atlas's dialyzability and post-transplant guidance rests on other sources.KDIGOExecutive summary of the KDIGO 2021 Guideline for the Management of Glomerular DiseasesKidney Int 2021 · PMID 34556300Provides the staging/treatment framework for drug-associated glomerular lesions (e.g., bisphosphonate- and interferon-related collapsing FSGS, VEGF-inhibitor podocytopathy/proteinuria), including immunosuppression and supportive RAAS-blockade strategies.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated VasculitisKidney Int 2024 · PMID 38388147Updates immunosuppressive induction (rituximab/cyclophosphamide), incorporates avacopan and lower-dose or glucocorticoid-sparing regimens — the management framework for drug- and checkpoint-inhibitor-associated ANCA/pauci-immune glomerulonephritis.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus NephritisKidney Int 2024 · PMID 38182299Updates first-line lupus nephritis therapy to combination immunosuppression with the addition of belimumab or a calcineurin inhibitor (voclosporin) — informs management of immune-complex/lupus-like glomerulonephritis encountered with immunotherapy.KDIGOExecutive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)Kidney Int 2025 · PMID 40975525Encourages liberal kidney biopsy and stricter proteinuria control (<0.5 g/d, ideally <0.3 g/d) with RAAS blockers, SGLT2 inhibitors, and targeted-release budesonide — the framework for IgA-dominant glomerular lesions, including those triggered by immune-modulating cancer therapy.

Where Cetuximab sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.

Position is a 2-D projection (MDS) of each agent's injury signature, nephron target, severity, and class, so two dots can sit close on the page while differing on an axis the projection flattened — the numbered ranking is computed from the full metric, not from the distance you see. Open the full map.

Phenotype-similar agents· the numbered markers on the map above

Panitumumab

Vectibix · Anti-EGFR antibody

Profile

TRPM6 magnesium wasting — heavier than cetuximab.

LYTEGLOM

Mild#1 · 100% phenotype match

Necitumumab

Portrazza · Anti-EGFR antibody

Profile

Severe hypomagnesemia, class effect.

LYTE

Moderate#2 · 71% phenotype match

Temsirolimus

Torisel · mTOR inhibitor

Profile

Proteinuria and glomerular effects; less firmly quantified than everolimus.

GLOMLYTE

Mild#3 · 64% phenotype match

Amivantamab

Rybrevant · EGFR-MET bispecific antibody

Profile

EGFR-mediated electrolyte (magnesium) wasting; an emerging acute interstitial nephritis signal is also clinician-flagged.

LYTEAIN

Moderate#4 · 60% phenotype match

Denosumab

Xgeva · Anti-RANKL antibody

Profile

Severe hypocalcemia in low GFR; not directly nephrotoxic.

LYTE

Moderate#5 · 60% phenotype match

Melphalan

Alkeran · Alkylator

Profile

SIADH in high-dose myeloma conditioning; renally cleared.

SIADHLYTE

Mild#6 · 57% phenotype match

Compare Cetuximab with its nearest agents

Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.

Kidney risk across Monoclonal antibodies (other)

Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile.

A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.

Who studies this

The leading contributors to Cetuximab’s clinical kidney literature on PubMed, ranked by a blend of publication volume and citation impact — filtered toward clinical work via the PubMed Humans heading and clinical publication types (trials, cohorts, case reports, guidelines, reviews). Names link to that author’s work on Cetuximab; the PMIDs beside each name are up to three of their most recent papers on it, not the full count.

Ranked by a 50/50 blend of publication volume and a position-weighted, capped Relative Citation Ratio (NIH iCite) on this agent’s renal literature; the citation count shown is the raw total, not the ranking score — counted over the 39 clinical records among all 48 PubMed matches, so counts are within-sample — bibliometric context, not an endorsement or a measure of clinical authority.